Neovasc to Participate in 10th Annual SVB Leerink Global Healthcare Conference
February 17 2021 - 9:00AM
via NewMediaWire -- Neovasc Inc. (NASDAQ, TSX: NVCN), today
announced that company management will be participating in the 10th
Annual SVB Leerink Global Healthcare Conference that is scheduled
to take place from February 24 to 26, 2021. Fred Colen, Neovasc’s
President and Chief Executive Officer, will present on Friday,
February 26, 2021 at 1:00 pm EST.
A link to the live webcast of the presentation will be available
online from the investor relations section of the Neovasc website
at https://www.neovasc.com/investors/.
About Neovasc Inc.Neovasc is a specialty
medical device company that develops, manufactures and markets
products for the rapidly growing cardiovascular marketplace. The
Company is a leader in the development of minimally invasive
transcatheter mitral valve replacement technologies, and minimally
invasive devices for the treatment of refractory angina. Its
products include the Neovasc Reducer™, for the treatment of
refractory angina, which is not currently commercially available in
the United States (2 U.S. patients have been treated under
Compassionate Use) and has been commercially available in Europe
since 2015, and Tiara™, for the transcatheter treatment of mitral
valve disease, which is currently under clinical investigation in
the United States, Canada, Israel and Europe. For more information,
visit: www.neovasc.com.
InvestorsMike CavanaughWestwicke/ICR Phone:
+1.646.877.9641Mike.Cavanaugh@westwicke.com
MediaSean LeousWestwicke/ICR Phone:
+1.646.677.1839Sean.Leous@icrinc.com
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and applicable Canadian securities
laws that may not be based on historical fact. When used
herein, the words "expect", "anticipate", "estimate", "may",
"will", "should", "intend," "believe", and similar expressions, are
intended to identify forward-looking statements.
Forward-looking statements may involve, but are not limited to the
expansion of its product range and the growing cardiovascular
marketplace. Forward-looking statements are based on estimates and
assumptions made by the Company in light of its experience and its
perception of historical trends, current conditions and expected
future developments, as well as other factors that the Company
believes are appropriate in the circumstances. Many factors
could cause the Company's actual results, performance or
achievements to differ materially from those expressed or implied
by the forward-looking statements, including those described in the
"Risk Factors" section of the Company's Annual Report on Form 20-F
and in the Management's Discussion and Analysis for the three and
nine months ended September 30, 2020 (copies of which may be
obtained at www.sedar.com or www.sec.gov). These factors
should be considered carefully, and readers should not place undue
reliance on the Company's forward-looking statements. The Company
has no intention and undertakes no obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Sep 2023 to Sep 2024